Brief: Poxel Announces Favorable PXL065 Phase 1a Trial Results

Poxel SA

12/11/2019 12:47

Nov 12 (Reuters) - POXEL SA  POXEL.PA :
    * PXL065 OBSERVED TO HAVE A FAVORABLE SAFETY, TOLERABILITY
AND
PHARMACOKINETIC (PK) PROFILE IN PHASE 1A TRIAL
    * WE PLAN TO INITIATE A PHASE 2 TRIAL FOR PXL065 IN
BIOPSY-PROVEN
NASH PATIENTS DURING Q2 OF 2020
    * PXL065 INTENDS TO UTILIZE 505(B) REGULATORY PATHWAY, WHICH
OFFERS OPPORTUNITY FOR A STREAMLINED AND EFFICIENT DEVELOPMENT
PLAN

Source text for Eikon:  ID:nBw9KMbrca 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))